SEARCH

SEARCH BY CITATION

References

  • Ausubel LJ, Krieger JI & Hafler DA (1997) Changes in cytokine secretion induced by altered peptide ligands of myelin basic protein peptide 85-99. J Immunol 159: 25022512.
  • Bein M, Schaller M & Korting HC (2002) The secreted aspartic proteinases as a new target in the therapy of candidiasis. Curr Drug Targets 3: 351357.
  • Boyaka PN, Marinaro M, Vancott JL, Takahashi I, Fujihashi K, Yamamoto M, van Ginkel FW, Jackson RJ, Kiyono H & McGhee JR (1999) Strategies for mucosal vaccine development. Am J Trop Med Hyg 60: 3545.
  • Bromuro C, La Valle R, Sandini S, Urbani F, Ausiello CM, Morelli L, Fè d'Ostiani C, Romani L & Cassone A (1998) A 70-kDa recombinant heat shock protein of Candida albicans is highly immunogenic and enhances systemic murine candidiasis. Infect Immun 66: 21542162.
  • Cassone A (2008) Fungal vaccine: real progress from real challenges. Lancet Infect Dis 8: 114124.
  • Cassone A, Boccanera M, Adriani D, Santoni G & De Bernardis F (1995) Rat clearing a vaginal infection by Candida albicans acquired specific antibody-mediated resistance to vaginal reinfection. Infect Immun 63: 26192625.
  • Cassone A, De Bernardis F & Torosantucci A (2005) An outline of the role of anti-Candida antibodies within the context of passive immunization and protection from candidiasis. Curr Mol Med 5: 377382.
  • Cassone A, De Bernardis F & Santoni G (2007) Anticandidal immunity and vaginitis: novel chances for immune intervention. Infect Immun 75: 46754686.
  • Cutler JE (2005) Defining criteria for anti-mannan antibodies to protect against candidiasis. Curr Mol Med 5: 383392.
  • Cutler JE, Deepe GS & Klein BS (2007) Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 5: 1328.
  • Dan MJ & Levitz SM (2006) Prospects for development of vaccines against fungal diseases. Drug Resist Update 9: 105110.
  • De Bernardis F & Boccanera M (2002) Mucosal infection and immunity in candidiasis. Fungal Pathogenesis: Principles and Clinical Applications (CalderoneR & ChilarR, eds), pp. 461482. Marcell Dekker Inc, New York, NY.
  • De Bernardis F, Boccanera M, Adriani D, Spreghini E, Santoni G & Cassone A (1997) Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 68: 32973304.
  • De Bernardis F, Lorenzini R & Cassone A (1999) Rat model of Candida vaginal infection. Handbook of Animal Models of Infection (Otozak & SandeMerle A, eds), pp. 735740. Academic Press, New York, NY.
  • De Bernardis F, Santoni G, Boccanera M, Spreghini E, Adriani D, Morelli L & Cassone A (2000) Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun 68: 32973304.
  • De Bernardis F, Sullivan PA & Cassone A (2001) Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol 39: 303313.
  • De Bernardis F, Boccanera M, Adriani D, Girolamo A & Cassone A (2002) Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun 70: 27252729.
  • De Bernardis F, Liu H, O'Mahony R et al. (2007) Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis 195: 149157.
  • De Bernardis F, Santoni G, Boccanera M, Lucciarini R, Arancia S, Sandini S, Amantini C & Cassone A (2010) Protection against rat vaginal Candidiasis by adoptive transfer of vaginal B lymphocytes. FEMS Yeast Res 10: 432440.
  • Elson CO (1989) Cholera toxin and its subunits as potential as potential oral adjuvants. Immunol Today 146: 2933.
  • Elson CO (1996) Cholera toxin as mucosal adjuvant. Mucosal Vaccines (KiyonoH, OgraPL & McGheeJR, eds), pp. 5972. Academic Press Inc, San Diego, CA.
  • Hochuli E, Banwarth W, Dobli H, Gentz R & Stuber D (1988) Genetic approach to facilitate purification of recombinant proteins with a novel metal-chelate absorbant. Bio/Technology 6: 13211325.
  • Horenstein AL, Crivellin F, Funaro A, Said M & Malavasi F (2003) Design and scale-up of downstream processing of monoclonal antibodies for cancer therapy: from research to clinical proof of principle. J Immunol Methods 275: 99112.
  • La Valle R, Sandini S, Gomez MJ, Mondello F, Romagnoli G, Nisini R & Cassone A (2000) Generation of recombinant 65-kDa mannoprotein (MP65), a major antigen target of cell-mediated immune response to Candida albicans. Infect Immun 68: 67776784.
  • Malavasi F, Caligaris-Cappio F, Milanese C, Dellabona P, Richiardi P & Carbonara AO (1984) Characterization of a murine monoclonal antibody specific for human early lymphohemopoietic cells. Hum Immunol 9: 920.
  • Martins MD, Lozano-Chiu M & Rex JH (1998) Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 27: 12911294.
  • McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD & Warnock DW (2001) Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis 33: 641647.
  • Naglik JR, Challacombe SJ & Hube B (2003) Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol R 67: 400428.
  • Naglik JR, Moyes D, Makwana J et al. (2008) Quantitative expression of the Candida albicans secreted aspartyl proteinase gene family in human oral and vaginal candidiasis. Microbiology 154: 32663280.
  • Nisini R, Romagnoli G, Gomez MJ, La Valle R, Mariotti S, Teloni R & Cassone A (2001) Antigenic properties and processing requirements of 65-kilodalton mannoprotein, a major antigen target of anti-Candida human T-cell response, as disclosed by specific human T-cell clones. Infect Immun 69: 37283736.
  • Nucci M & Marr KA (2005) Emerging fungal diseases. Clin Infect Dis 41: 521526.
  • Perbal B (1988) A Practical Guide to Molecular Cloning. Wiley-Interscience Publications, New York, NY.
  • Pfaller MA & Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133163.
  • Powderly WG, Mayer KH & Perfect JR (1999) Diagnosis and treatment of oropharyngeal candidiasis in patients infected with HIV: a critical reassessment. AIDS Res Hum Retrov 15: 14051412.
  • Ross IK, De Bernardis F, Emerson GW, Cassone A & Sullivan PA (1990) The secreted aspartate proteinase of Candida albicans: physiology of secretion and virulence of a proteinase-deficient mutant. J Gen Microbiol 136: 687694.
  • Sandini S, Melchionna R, Arancia S, Gomez MJ & La Valle R (1999) Generation of a highly immunogenic recombinant enolase of the human opportunistic pathogen Candida albicans. Biotechnol Appl Bioc 29: 223227.
  • Sandini S, La Valle R, De Bernardis F, Macrì C & Cassone A (2007) The 65-kilodalton mannoprotein gene of Candida albicans encodes a putative β-glucanase adhesin required for hyphal morphogenesis and experimental pathogenicity. Cell Microbiol 9: 12231238.
  • Santoni G, Boccanera M, Adriani D, Lucciarini R, Amantini C, Cassone A & De Bernardis F (2002) Immune-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4+T cells and possible participation of other local lymphocyte effectors. Infect Immun 70: 47914797.
  • Stringaro A, Crateri P, Pellegrini G, Arancia G, Cassone A & De Bernardis F (1997) Ultrastructural localization of the secretory aspartyl proteinase in Candida albicans cell wall in vitro and in experimentally infected rat vagina. Mycopathologia 137: 95107.
  • Stuber D, Matile H & Garotta G (1990) System for high-level production in E. coli and rapid purification of recombinant proteins:application to epitope mapping preparation of antibodies and structure/function analysis. Immunological Methods (LefkovitzI & PernisB, eds), pp. 122151. Academic Press Inc, Orlando, FL.
  • Trabocchi A, Mannino C, Machetti F, De Bernardis S, Cauda R, Cassone A & Guarna A (2010) Identification of inhibitors of pharmacoresistant Candida albicans strains from a library of bicyclic peptidomimetic compounds. J Med Chem 53: 25022509.
  • Vilanova M, Teixeira L, Caramalho I, Torrado E, Marques A, Madureira P, Ribeiro A, Ferreira P, Gama M & Demengeot J (2004) Protection against systemic candidiasis in mice immunized with secreted aspartic proteinase 2. Immunity 111: 334342.